PATH proposes to use existing reagents and experience in potency method development for global use to optimize mRNA vaccine potency methods for both monovalent and multivalent SARS-CoV-2 vaccines.
Identify critical parameters for cell culture transfection and establish specification criteria to ensure consistent antigen production
Optimize the mRNA transfection process to ensure standardization of antigen expression in selected cell lines
Optimize ELISAs for quantification of monovalent and multivalent vaccine antigens
Not yet a member? Learn more about which level of NIIMBL membership is right for you and your organization.
PATH Center for Vaccines Innovation & Access